3-溴-5-乙氧基苯甲酸 | 855198-27-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-5-乙氧基苯甲酸
• 英文名称: 3-bromo-5-ethoxybenzoic acid
• 英文别名: 3-ethoxy-5-bromo-benzoic acid；3-Aethoxy-5-brom-benzoesaeure
• CAS: 855198-27-5
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: DMIGIIGQWXKUKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-溴-5-乙氧基苯甲酸 在 sodium tetrahydroborate 、 palladium diacetate 、 sodium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 甲醇 、 乙醇 、 二丁醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 95.0h， 生成 (RS)-1-(3-(3,5-dimethylisoxazol-4-yl)-5-ethoxyphenyl)ethanol
  参考文献：
  名称：

  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands

  摘要：

  Histone-lysine acetylation is a vital chromatin post-translational modification involved in the epigenetic regulation of gene transcription. Bromodomains bind acetylated lysines, acting as readers of the histone-acetylation code. Competitive inhibitors of this interaction have antiproliferative and anti-inflammatory properties. With 57 distinct bromodomains known, the discovery of subtype-selective inhibitors of the histone bromodomain interaction is of great importance. We have identified the 3,5-dimethylisoxazole moiety as a novel acetyl-lysine bioisostere, which displaces acetylated histone-mimicking peptides from bromodomains. Using X-ray crystallographic analysis, we have determined the interactions responsible for the activity and selectivity of 4-substituted 3,5-dimethylisoxazoles against a selection of phylogenetically diverse bromodomains. By exploiting these interactions, we have developed compound 4d, which has IC50 values of < 5 mu M for the bromodomain-containing proteins BRD2(1) and BRD4(1). These compounds are promising leads for the further development of selective probes for the bromodomain and extra C-terminal domain (BET) family and CREBBP bromodomains.

  DOI：

  10.1021/jm200640v
• 作为产物：
  描述：

  3-溴-5-乙氧基苯甲酸乙酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以97%的产率得到3-溴-5-乙氧基苯甲酸
  参考文献：
  名称：

  [EN] HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
  [FR] DÉRIVÉS D'HYDROXY FORMAMIDE ET LEUR UTILISATION

  摘要：

  揭示了具有以下化学式的化合物：(I)，其中R1、R2和R3如本文所定义，并且揭示了制备和使用这些化合物的方法，包括用作BMP1、TLL1和/或TLL2的抑制剂以及用于治疗与BMP1、TLL1和/或TLL2活性相关的疾病。

  公开号：

  WO2017006295A1

文献信息

• 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES
  申请人：Andreini Matteo

  公开号：US20090209529A1

  公开（公告）日：2009-08-20

  The present invention relates to a compounds of formula I wherein R 1 , R 1′ , R 2 , R 3 , R 4 , X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及一种具有以下式I的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，R 4 ，X，Ar和m如规范和索赔中定义，并且其药用活性酸盐。本发明的化合物具有Asp2（β-分泌酶，BACE 1或Memapsin-2）抑制活性，并且对于治疗由β-淀粉样蛋白水平升高或β-淀粉样蛋白沉积所特征的疾病，特别是阿尔茨海默病，是有用的。
• HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

  公开号：US20160340328A1

  公开（公告）日：2016-11-24

  Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  揭示了具有以下公式的化合物：其中R1、R2和R3如本文所定义，并且制备和使用这些化合物的方法，包括用作BMP1、TLL1和/或TLL2的抑制剂以及用于治疗与BMP1、TLL1和/或TLL2活性相关的疾病。
• 4,5-dihydro-oxazol-2-yl amine derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US07989449B2

  公开（公告）日：2011-08-02

  The present invention relates to a compounds of formula I wherein R1, R1′, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及公式I的化合物，其中R1，R1'，R2，R3，R4，X，Ar和m如规范和要求中所定义，并且其药理活性酸盐。本发明的化合物具有Asp2（β-分泌酶，BACE 1或Memapsin-2）抑制活性，并且对于治疗β-淀粉样蛋白水平或β-淀粉样蛋白沉积物特别是阿尔茨海默病等疾病非常有用。
• Hydroxy formamide derivatives and their use
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

  公开号：US10450288B2

  公开（公告）日：2019-10-22

  Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  所公开的是具有以下式子的化合物 其中 R1、R2 和 R3 如本文所定义，以及制造和使用这些化合物的方法，包括用作 BMP1、TLL1 和/或 TLL2 的抑制剂以及治疗与 BMP1、TLL1 和/或 TLL2 活性有关的疾病。
• Piperazine derivatives as MAGL inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US11390610B2

  公开（公告）日：2022-07-19

  The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新杂环化合物或其药学上可接受的盐、 其中 R1、R2、X、Y1 和 Y2 如本文所述。